Alzheimer’s, the vaccine that restores memory and helps prevent disease
A vaccine that treats Alzheimer’s and can even prevent it. This is what they are proving a point to a group of British and German companies, which claim to have found a way to remedy the damage to the beta amyloid protein, the one that leads to the degenerative condition of the brain. The experiment has not yet been conducted in humans, but in mice it gave excellent results as the protein was obtained and memory restored. Those who led them illustrated everything in an article published by the Mirror. Obviously the excellent results obtained on mice also be confirmed in human studies; therefore, there is still a long way to go. According to Professor Mark Carr of the University of Leicester, the author study may, however, open up the possibility of not treating Alzheimer’s, but also of vaccinating against the disease before symptoms appear. Vaccine that could cost as little as 15 pounds (around 18 euros).
WHAT IS THE ALZHEIMER
Alzheimer’s disease is a neurodegenerative disease caused by loss of memory and intellectual-motor skills, contradicts the occurrence of brain cells. He begins mainly after the age of 65 but in the juvenile forms, even if rarer, symptoms can begin to appear from the age of 50.
The symptom that characterizes the early stage of Alzheimer’s is memory loss, which manifests itself with difficulty in remembering recent information and events. Initially the patient remembers things learned years before the onset of the disease but has difficulty in acquiring new information and fixing it in memory. In the next phase the disorder becomes more pervasive because the patient begins to forget even more ancient facts of his personal life, does not recognize places and people familiar to him, the language becomes impoverished, has no initiative and becomes apathetic.
Is called Tapas and is an innovative and protein-based vaccine that could fight Alzheimer’s. This encouraging result emerges from one studio, published in the journal Molecular Psychiatry, conducted by the studies of the University Medical Center of Leicester and the medical research charity LifeArc. The team, led by Thomas Bayer, has developed a therapy to fight Alzheimer’s disease and a vaccine that could prevent the disease from appearing.
“In clinical studies conducted neglect – observes Bayer, of the University Medical Center of Gottingen – none of the potential treatments aimed at dissolving amyloid plaques present in the brain presented showed statistically significant effects in preventing or counteracting Alzheimer’s symptoms. Some have the possibility of negative side effects. We therefore chose a different approachThe researchers have protein-based treatments and a vaccine, which interfaces with a local protein in proteins associated with the onset of Alzheimer’s.Beta amyloid protein, the authors explain, is associated with a higher risk of developing Alzheimer’s disease when it reaches high concentrations.“.
“We used the Tap01_04 antibody – explains Marco Carr, of the Leicester Institute of Structural and Chemical Biology at the University of Leicester – and beta amyloid folded into itself into a well-defined configuration that had never been observed before. This hairpin-shaped structure allowed us to engineer this region of the protein and stabilize the beta amyloid so that it binds to the antibody.“.
The researchers experimented with the vaccine on rodents to underestimate the effectiveness of the treatment. The mice that received the therapy, not the researchers, produced a TAP01-type support. The engineering form amyloid was then used as a vaccine for the immune system and began the production of specific betas. The research team tested the antibody and the engineered beta-amyloid vaccine in several specimens, using imaging techniques to ascertain the effectiveness of the two products.
The team points out that the vaccine and antibody helped restore neuronal function by increasing glucose metabolism in the brain, reactivating memory circuits and reducing beta amyloid plaque formation.
“The 01_04 antibody and the TAPAS vaccine are very different from the Alzheimer’s treatments developed so far – declared the dr. Bakrania by LifeArc – because they target a different form of the protein. This makes them very promising as a potential treatment for the disease as both a therapeutic antibody and a vaccine. If the treatment is successful, the lives of many patients could be transformed“Regarding the possibility of replicating clinical results on humans, the results reveal an enthusiasm, the treatment.”Opening up the possibility of not only treating Alzheimer’s once symptoms are detected, but also getting vaccinated against the disease before symptoms appear“concluded Carr.
Benedetta de Mattei